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Prostate cancer is a complex and heterogeneous disease, and
it is the most prevalent form of cancer and the second leading
cause of cancer death in men (1). Along with the classic methods of diagnosing and prognosticating prostate cancer, utilizing
stage, grade, and serum prostate-specific antigen level, molecular markers of aggressive disease are currently being evaluated as adjuncts to improve identification of tumors associated
with a poor outcome. Because abnormal regulation of the cell
cycle is one of the major causes of tumorigenesis in recent
years, major advances have been made to understand the molecular mechanisms of aberrant cell cycle control leading to the
development and progression of tumors. Studies on the aberrant expression of cell cycle regulatory genes in prostate carci-
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noma have identified a cdk1 inhibitor p27kip1 (2) and p53 (3) as
biomarkers. These markers show a strong correlation with a
high, moderate, or low risk of occurrence of prostate cancer.
Immunohistochemical analysis of other G1/S check point-controlling proteins, including cyclins (4), the cdk inhibitor p16 (5),
and retinoblastoma (6), have also been found to be helpful in
identifying patients with aggressive prostate cancer.
One of the major underlying mechanisms of aberrant cell
cycle progression is uncontrolled DNA replication irrespective
of cellular signals as a result of G1/S checkpoint failure. DNA
replication is a highly ordered event controlled by sequential
binding to and release of a number of replication proteins from
the DNA sequence close to the origin of DNA replication. This
also restricts firing of the replication origin to once per cell
cycle. The regulation of initiation of DNA replication has been
studied extensively in Saccharomyces cerevisiae, whereas understanding of this regulation in the mammalian system has
just begun. However, identification of human homologs of yeast
replication proteins, such as origin recognition complex (7–10),
CDC6 (11), and minichromosome maintenance proteins (MCM)
(12, 13), suggests evolutionarily conserved replication machinery. Studies on DNA replication in S. cerevisiae and Xenopus
laevis have established a critical role of CDC6 in the initiation
of replication (14 –16). In late mitosis, when mitotic cyclin
(cyclin B) and cdk are inactive, CDC6 helps to establish the
prereplicative complex (Pre-RC) on the chromatin-bound origin
recognition complex, a six-subunit initiator protein (17), by
recruiting MCM proteins and other factors (18 –20). In middle
to late G1 and at the G1/S transition, S-phase cyclins (cyclin E
and cyclin A) and cdk2 are expressed (21, 22) and initiate DNA
replication by phosphorylating CDC6, which causes it to dissociate from Pre-RC (23). Release of CDC6 from chromatin and
its translocation to the cytoplasm triggers initiation of DNA
replication (24). Another role of CDC6 in S. cerevisiae is to
function as an inhibitor of the G2/M phase until the S phase is
complete (25). This defines CDC6 as a unique and critical
protein with a dual role in regulating both G1/S and G2/S
checkpoints.
The regulation of CDC6 expression throughout the cell cycle
in mammalian cells, however, is quite different than that observed in proliferating yeast. In yeast, most of the phosphorylated CDC6 at the G1/S boundary is degraded by ubiquitination,
whereas in mammalian cells, a fraction of phosphorylated
CDC6 remains bound to chromatin throughout the cell cycle

1
The abbreviations used are: cdk, cyclin-dependent kinase; RLU,
relative luminescence unit; MCM, minichromosome maintenance protein; Pre-RC, prereplicative complex; RT, reverse transcriptase; AUC,
area under the receiver operating characteristic curve; PIN, prostatic
intraepithelial neoplasia.
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CDC6 plays a critical role in regulation of the onset of
DNA replication in eukaryotic cells. We have found that
Cdc6 expression is down-regulated in prostate cancer as
detected by semiquantitative reverse transcriptasePCR of prostate cell lines and laser-captured microdissected prostate tissues. This result was substantiated by
immunohistochemical analysis of paraffin-embedded
tissue sections and immunoblot analysis of benign
(BPH-1) and adenocarcinomatous prostatic cells. Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was
noted in the metastatic PC3 cells compared with that in
BPH-1 cells. Concentration of the E2F and Oct1 transcription factors that have putative binding sites in the
Cdc6 promoter was substantially low in PC3 cells compared with BPH cells. Mutagenesis of the two E2F binding sites on the Cdc6 promoter resulted in increased
promoter activity in PC3 cells owing to elimination of
the negative regulation by pRb䡠E2F complex but not to
the level of that obtained in BPH cells. We conclude that
an altered interaction of transcription factors may be
responsible for the down-regulation of Cdc6 transcription in PC3 cells. Our study suggests a potential use of
the lack of CDC6 expression as an index of prostate
cancer development.
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EXPERIMENTAL PROCEDURES

Cell Lines—Three commercially available cell lines, LNCaP, DU145,
and PC3 (ATCC) were cultured in RPMI 1640 (LNCaP and DU145) and
in Ham’s F-12 (PC3) with 10% fetal bovine serum and penicillin/streptomycin. A benign prostatic hyperplasia cell line, BPH-1 (a gift from P.
Narayan, University of Florida, Gainesville, FL) (34), was maintained
in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum
and penicillin/streptomycin. A metastatic cell line, MDAPCa2a (M.D.
Anderson Cancer Center, Houston, TX) (35) was maintained in BRFFHPC1 (Biological Research Faculty and Facility, Inc. Jamesville, MD)
medium containing 20% fetal bovine serum and gentamicin. BRFF
medium contains cholera toxin, insulin, epidermal growth factor, and
hydrocortisone. Total RNA was extracted from cell lines using an RNA
extraction kit (RNAgents, Stratagene) according to the manufacturer’s
protocol. Genomic DNA from BPH-1 and PC3 cells was extracted using
a genomic DNA isolation kit (Puregene DNA Isolation kit, Gentra
Systems) according to the manufacturer’s instructions.
Tissue Samples and Laser Capture Microdissection—Approximately
400 –5000 cells were captured from prostate cancer or histologically
normal prostatic epithelium using a Pix cell II laser capture microdissection system (Arcturus Engineering, Mountainview, CA). Frozen sections of prostate tissue from radical prostetectomy were used for microdissection of normal and cancerous areas on the basis of histologic
features of normal or carcinomatous epithelia following staining with
hematoxylin and eosin stain. Cells were microdissected rapidly from
each frozen section in an RNase-free environment to avoid RNA
degradation
Northern Hybridization and Semiquantitative RT-PCR—Twenty micrograms of total RNA from BPH-1, LNCaP, and PC3 cell lines was
used for Northern blot using a standard procedure. A 1.6-kb clone of
human Cdc6 cDNA was used as the probe for hybridization.
For semiquantitative RT-PCR, BPH-1, DU145, and MDAPCa2a cells
and laser capture microdissected tissue samples obtained from radical
prostetectomies were used. Total RNA was extracted using Stat 60
(Tel-Test Inc.) and used for RT reaction using oligo(dT) primer and 18

S RNA primer pairs and their competimers (Quantum RNA, Ambion)
and Superscript II reverse transcriptase (Invitrogen). The 18 S primers
were used to yield a 489-bp fragment of 18 S rRNA as an internal
control, and total RNA from BPH cells was used as the positive control.
A Cdc6 gene-specific forward (5⬘-CTGGAGTTTGCTGCTGCCGCT-3⬘)
and reverse (5⬘-GAGCACCAGAAAGGTAAAGGC-3⬘) primer pair was
used to yield an 811-bp fragment. Amplified fragments were visualized
by Southern blot using Cdc6 and 18 S cDNAs as probes. Positive signals
were quantified in a PhosphorImager (Amersham Biosciences) and
normalized with the relative values of 18 S RNA signal.
Cloning of Cdc6 Promoter and Expression of Luciferase Gene—For
Cdc6 promoter-luciferase constructs, the Cdc6 promoter region spanning positions ⫺1436 to ⫹218 was amplified by genomic PCR using
genomic DNA from BPH-1 cells as the template, Taq-Pfu polymerase
(Stratagene) (19:1 mixture), and primers (F5⬘-GCAGCCCATTCTCTTCACTTTTCG-3⬘ and R5⬘-GCTCTTTTCCCTTCACTTCACCTC-3⬘). The
amplified product was cloned into pGL3 basic firefly luciferase vector
(Promega) between SstI and HindIII sites and designated as construct
C. Two other deletion constructs, construct B and construct A, containing the promoter fragments ranging from ⫺794 to ⫹218 and ⫺391
to ⫹218, respectively, were made. Fidelity of the amplified Ccd6
promoter sequence was confirmed by dideoxy chain termination sequencing using an ABI 310 sequence analyzer (PE Biosystems), and
putative transcription factor binding sites were identified using an
online program (www.bioinformatik.de). Four more constructs designated as D (NFB), E (C/EBP), F (NF1), and G (Oct1) were made by PCR
amplification to map the region between ⫺1436 and ⫺794 bases according to the putative transcription factor binding sites. A set of
forward primers containing SstI restriction site (NFB, 5⬘-GAGCTCTAAAAACTCAGC-3⬘; C/EBP, 5⬘-GAGCTCGCGCTAATTTATATTTTTCAT-3⬘; NF1, 5⬘-GAGCTCGGTGATGTAGGTAAAATAC-3⬘; and Oct1, 5⬘GAGCTCCCTCATTTGTAAAGTGAAATAACA-3⬘) and a common reverse primer containing a HindII restriction site (5⬘-AACAGTACCGGAATGCCAAG-3⬘) were used for directional cloning. The construct C
was used as the template.
A PCR-based mutagenesis method described in the QuikChange kit
(Stratagene) was used to substitute nucleotides in two E2F binding
sites at positions ⫺43 to ⫺36 and ⫺8 to ⫺1 from the transcription start
site. The E2F binding motif TTTGGCGG in both locations was converted to TTTGAAGG in construct C and used for transfection.
Both BPH and PC3 cells were grown to 80% confluency and used for
transient transfection with the pGL3 constructs and pRL-TK (Promega)
as an internal control vector using LipofectAMINE (Life Technologies)
according to the manufacturer’s specification. Transfected cells were
maintained in the culture media and harvested between 48 and 72 h,
and luciferase expression was monitored using a Dual Luciferase assay
kit (Promega) according the supplier’s protocol. Relative luminescence
from the expressed luciferase was normalized with the expression of
Renilla luciferase. Transfection efficiencies were calculated as the relative luminescence unit (RLU) ratio of pGL3 constructs over that of
pGL3 basic vector.
Preparation of Crude Cell, Cytoplasmic, and Nuclear Extract—
BPH-1 and PC3 cells were grown to 80% confluency and harvested
using freeze-thaw cycle in a lysis buffer (50 mM Tris-HCl, pH 8.0, 120
mM NaCl, 2.5 mM EDTA, pH 8.0, 1 mM phenylmethylsulfonyl fluoride,
0.4% Nonidet P-40, and 2 ml/ml of the protease inhibitor mixture Set III
(Calbiochem)). Crude cell lysates were centrifuged at 16,000 ⫻ g for 10
min at 4 °C to remove cellular debris. For cytoplasmic and nuclear
extract, 100 l of packed cell volume of each cell and nuclear and
cytoplasmic extraction reagents (NE-PER, Pierce) were used according
to the manufacturer’s protocol. Cytoplasmic fractions in the supernatant were collected and stored at ⫺80 °C until use. Nuclear pellets were
collected and lysed by vortexing in a lysis buffer NER (Pierce), and
soluble proteins were separated in the supernatant by centrifugation at
14,000 ⫻ g for 10 min at 4 °C. Supernatants were stored at ⫺80 °C until
use for Western blot analysis.
Immunoblot and Immunohistochemistry—Total cell extracts from
asynchronous cultures of BPH-1 and PC3 were used for immunoblot
analysis using a standard procedure. 50 g of total protein and antibodies against CDC6 (a gift from Dr. Anindya Dutta, Harvard Medical
School and Oncogene Research Products, La Jolla, CA), E2F1 (Santa
Cruz Biotechnology Inc., Santa Cruz, CA), NF1, NFB, C/EBP alpha,
and Oct1 (Geneka Biotechnology Inc., Montreal, Quebec, Canada) were
used to monitor expression of specific proteins. A chemiluminescence
detection kit (Pierce) was used to detect positive signals recognized by
specific antibodies using either a goat anti-mouse or a goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody. For immunohistochemistry, paraffin-embedded tissue sections of normal and ma-
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and prevents reloading of MCM protein until the end of mitosis
when degradation of mitotic cyclin occurs (26). Maintenance of
a cytoplasmic pool of hypophosphorylated CDC6 has been proposed in a model for CDC6 regulation in mammalian cells (26),
although its role in the reassembly of Pre-RC in the next round
of DNA replication or in delaying the M phase is elusive. Being
a key regulator of DNA replication and the G2/M checkpoint,
CDC6 expression needs to be tightly regulated for normal cell
cycle progression. Several lines of evidence indicate that a gain
in expression of CDC6 leads to increased DNA synthesis (27–
29), leading to the designation of CDC6 as a proliferation
marker. On the other hand, loss of expression of CDC6 has
been shown to cause chromosomal loss and a lack of G2/M
checkpoint control resulting in abnormal daughter cells (11,
31). Although an important component of the cell cycle regulatory mechanism, potential involvement of CDC6 in carcinogenesis has been investigated only recently. Recent reports on the
overexpression of CDC6 and MCM proteins in low grade and
high grade squamous intraepithelial neoplasia of cervix and
brain tumors suggested their possible use as proliferation
markers for detecting abnormal precursor malignant cells in
cervical smears and tumors in brain tissues (32, 33). These
reports suggest a possible role for CDC6 in carcinogenesis and
cancer progression.
Using differential display of mRNA and cDNA microarrays,
we have identified altered expression of CDC6 in prostate
cancer cell lines. Here we report loss of CDC6 transcription as
an event toward acquiring a cancerous phenotype of prostatic
epithelium as observed by immunohistochemistry of tissue sections and semiquantitative RT-PCR of laser-captured microdissected prostate tissues. We have used a cell line developed from
benign prostate hyperplasia and a prostate adenocarcinoma
cell line to elucidate the mechanism of down-regulation of
CDC6 expression in a prostate cancer cell line. We provide
evidence that the loss of Cdc6 transcription is due to suboptimal transcription not mutation at the promoter sequence.

Cdc6 Expression in Prostate Cancer
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FIG. 1. Expression of CDC6 in benign prostatic hyperplasia
and prostate cancer cells. A, RNA blot analysis of Cdc6 mRNA in
BPH, LNCaP, and PC3 cells. B, RT-PCR analysis of Cdc6 transcripts in
BPH, DU145, and MDAPCa2a cells. C, densitometric analysis of the
autoradiogram shown in B. D and E, Western blot analyses of CDC6 in
BPH and PC3 cells using 50 g of protein for each extract. WH, whole
cell extracts; Cyto, cytoplasmic extract; Nuc, nuclear extract.
lignant prostate were subjected to a pepsin-based antigen retrieval
protocol (BioGenex, San Ramon, CA) followed by incubation with antiCDC6 antibody. A biotinylated multilink goat anti-immunoglobulin for
mouse, rabbit, guinea pig, and rat was used as the secondary antibody.
Positive signals were detected by horseradish peroxidase-conjugated
streptavidin and 3,3⬘-diaminobenzidine (DAB) as the chromagen (BioGenex Multi-Link kit).
Statistical Analysis—Univariate receiver operating characteristic
analyses were carried out for the log 10 value for Cdc6 expression in
uninvolved and adenocarcinoma tissue samples to examine their utility
for predicting an uninvolved (yes/no) outcome. The sensitivity and specificity trade-offs were summarized using the area under the receiver
operating characteristic curve, denoted AUC, and calculated via a logistic regression model (36). An AUC value of 1.0 corresponds to an
excellent predictive model, whereas an AUC value of 0.5 corresponds to
a poor predictive model.
RESULTS

Cdc6 Expression Is Down-regulated in Prostate Cancer
Cells—In our effort to identify differentially expressed genes in
prostate cancer using differential display RT-PCR and cDNA
microarray technology, we identified Cdc6 as one of the candidate genes that are down-regulated in prostate cancer. A gradual loss of the steady-state Cdc6 mRNA concentration was
detected by differential display RT-PCR in LNCaP and PC3
cells when compared with that in BPH-1 cells. This result was
further confirmed by RNA blot analysis (Fig. 1A). In addition,
a reduced concentration of Cdc6 transcript (ratio of expression:

31.2) in a metastatic prostate cancer cell line, MDAPCa2a,
compared with a normal prostate cell line, PrEC, has been
detected by hybridization to a cDNA microarray of 18,376 nonredundant clones (data not shown). Down-regulation of Cdc6
was also evident from semiquantitative RT-PCR followed by
densitometric analysis of Cdc6 mRNA present in DU145 and
MDAPCa2a cells (Fig. 1, B and C). The data showed a significant loss of the Cdc6 steady-state transcript level in
MDAPCa2a cells but a moderate reduction of the same in
DU145 cells. Western blot analysis of CDC6 using an antiCDC6 antibody further confirmed the loss of CDC6 expression
in the metastatic PC3 cells compared with the benign BPH-1
(Fig. 1D). The upper band in the BPH-1 whole cell extract lane
(Fig. 1D) is probably the phosphorylated form of CDC6, because
human CDC6 does not become degraded upon inactivation by
phosphorylation as observed in S. cerevisiae. Analysis of the
distribution of CDC6 in subcellular fractions showed an accumulation of CDC6 in the nuclear fraction of BPH-1 cells as
expected and a substantial reduction of CDC6 in both nuclear
and cytoplasmic fractions of PC3 cells (Fig. 1E).
Reduced Concentration of Cdc6 Transcripts in Human Prostatic Adenocarcinoma Tissues—To validate the expression profile of Cdc6 in human prostatic adenocarcinoma, we have monitored Cdc6 mRNA concentration by semiquantitative RT-PCR
in histologically normal prostatic epithelium and prostatic adenocarcinoma. To ensure homogeneous cell populations, lasercaptured microdissected areas of histologically normal and carcinomatous tissues were used. Amplification of Cdc6 cDNA was
normalized by co-amplified 18 S ribosomal mRNA. 18 S competimers were used along with the specific 18 S primers to
maintain a comparable amplification intensity of the highly
abundant 18 S rRNA compared with a very low copy number of
the input RNA. Southern blot analysis followed by densitometric analysis of the amplified products showed a consistently
reduced expression of Cdc6 mRNA in adenocarcinoma tissues
compared with that in matched normal prostatic epithelium in
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FIG. 2. Semiquantitative RT-PCR analysis of Cdc6 transcripts
in LCM tissues. A, autoradiogram; B, densitometric analysis of relative Cdc6 transcript concentration after normalization with the amplified 18 S rRNA. The autoradiogram represents similar sample order.
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TABLE I
Correlation of Gleason scores with expression of Cdc6 transcripts
Expression of uninvolved
Cases

Gleason score
Matched tumors

Isolated tumors
%

Group 1
Group 2

6 (2)
7–9 (6), 6 (1)

51–72
0.13 –14

0.15–21
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six out of eight sample pairs tested (Fig. 2, A and B). Similar
final digits among the sample numbers designate matched
samples. In samples N4 and T4 and in P10 (prostate intraepithelial neoplasia) and T10, Cdc6 mRNA concentrations were
below the detection limit, whereas Cdc6 mRNA concentration
was higher in adenocarcinoma T5 than in the matched normal
epithelium N5. In adenocarcinoma samples without matching
normal epithelium, T9, T11, and T12, Cdc6 mRNA concentrations were lower than that in four out of seven normal epithelial samples (N3, N6, N7, and N8).
Loss of Cdc6 Transcripts Correlated Well with the Tumor
Characteristics and Pathological Report—Histologically normal prostate epithelium and adenocarcinomas were obtained
from radical prostetectomy specimens from patients with prostate cancer. The mean patient age at the time of surgery was
63.3 ⫾ 4.3 ranging between 55 and 71 years. The Gleason
scores of the adenocarcinoma ranged from 6 to 9 at the following frequencies: A Gleason score of 6 equals four tumors, a
Gleason score of 7 equals six tumors, and a Gleason score of 9
equals one tumor. The cases were divided into two groups: 1)
cases with organ-confined disease and no invasion into seminal
vesicle or bladder and 2) cases with extension of tumors to the
seminal vesicle or bladder. Group 1 tumors all had a Gleason
score of 6 (two) whereas group 2 tumors had a Gleason score of
7 or higher (six) and 6 (one). Analysis showed that group 2
tumors are associated with a significant loss of Cdc6 transcripts, ranging from 86 to 99% of that of the normal epithelium, whereas group 1 tumors exhibit a moderate loss of transcripts ranging from 28 to 50% of that measured in matched
histologically normal tissues (Table I). Carcinomas without
matching normal epithelium showed 79 –99% reduction in the
transcript concentration compared with the average concentration of all uninvolved tissues.
The univariate analysis of Cdc6 expression showed an odds
ratio of 3.1 and an AUC value of 0.800 (Table I). The higher the
AUC, the better the predictor; therefore, in the univariate case,
Cdc6 is a better predictor because the AUC is closer to 1.0. The
interpretation of the odds ratio is that for every 10-fold increase
in expression, the odds of being an uninvolved case relative to
not being uninvolved increases by the amount given above, e.g.
for every 10-fold increase in Cdc6, the odds of being uninvolved
as compared with uninvolved increased 3.1 to 1.
Reduced Expression of Cdc6 in Intact Histologic Sections of
Prostate Tissue—To correlate CDC6 expression with the histologic features of normal prostatic epithelium and prostatic adenocarcinoma, CDC6 proteins were detected in prostate tissue
samples by immunostaining using an anti-CDC6 antibody (Fig.
3). Tissue sections containing histologically normal epithelium,
adenocarcinoma, and prostatic intraepithelial neoplasia (PIN)
were chosen for comparative analysis. Areas with positive signals were compared with the H&E-stained, parallel sections for
accurate identification of normal and carcinomatous areas. As
shown in Fig, 3, normal epithelium showed a positive homogeneous staining for CDC6, with granular cytoplasmic and nuclear staining observed in the prostatic luminal cells (Fig. 3, A
and B). PIN also showed distinct staining similar to that observed in the histologically normal glands (Fig. 3, C and D). In
carcinoma, a significant reduction in overall staining for CDC6,

representing loss of expression can be seen (Fig. 3, E and F). A
similar expression pattern of CDC6 was observed in histologic
sections from eight different prostate tissues. This observation
is also in agreement with our semiquantitative RT-PCR analysis showing the reduced Cdc6 transcripts in prostate
adenocarcinoma.
Sub-optimal Transcription May Lead to Low Cdc6 Expression in PC3 Cells—To understand the regulation of CDC6
expression in PC3 cells, we conducted a luciferase gene assay
using a 1.654-kb fragment of Cdc6 promoter. Sequence analysis
of Cdc6 promoters amplified from PC3 and BPH-1 or from a
normal prostate cancer cell line (PrEC, Clonetics) did not show
any mutations (data not shown). Computer analysis of the
promoter sequence revealed a variety of putative transcription
factor binding sites, including E2F, Sp1, NF1, NF␤, Oct1, and
C/EBP (Fig. 4A), which may or may not be utilized in a particular cell line. Interestingly, the pGL3-Cdc6 construct C containing the entire 1.654-kb promoter fragment showed a considerable difference in luciferase expression upon transfection
of BPH-1 versus PC3 cells (Fig. 4B). Approximately 50- to
100-fold higher transcription efficiency (1040 ⫾ 128 versus
10 ⫾ 6) of construct C was noted in transfected BPH-1 cells
compared with that in PC3 cells. The construct B, containing a
truncated promoter of the 794-bp fragment, showed an overall
decline in the transcription efficiency compared with that obtained by the entire promoter, construct C, as expected. Although construct B was less efficient because of the lack of
three C/EBP, two NF1, one NFB, and one Oct1 binding sites,
a 16-fold difference in relative luminescence units (RLU)
(373 ⫾ 93 versus 22 ⫾ 16) was detected in BPH-1 cells compared with PC3 cells transfected with the same construct.
Construct A, composed of a 391-bp promoter fragment containing three E2F, three Sp1, and one NF1 sites, however, was
inefficient in driving the luciferase transcription in either cell
line. The RLU for construct A measured in both cell lines was
close to the basal RLU of the basic pGL3 without any promoter.
Although construct B did not have any putative transcription
factor binding sites, the additional 403-bp sequence in construct B was able to stimulate luciferase transcription, suggesting interaction/binding of unknown proteins with this region.
The control vector containing an SV40 promoter was equally
effective in luciferase transcription in both cell lines. Further
mapping of the upstream sequence showed a significant increase in the luciferase expression by the transfected BPH-1
cells following inclusion of the NFB binding site in construct B
(construct D) (Fig. 4B). Inclusion of the region containing a
C/EBP (construct E) binding site suppressed luciferase transcription substantially. Addition of the NF1 (construct F) and
Oct1 (construct G) binding sites increased transcription back to
the level obtained with construct C. Addition of two other
C/EBP sites (construct C) did not make any difference in the
level of luciferase transcription. None of the constructs were
able to improve transcription efficiency of the Cdc6 promoter
when transfected into PC3 cells, implying that the reduced
transcription of Cdc6 was not due to interaction of any negative
regulators with the Cdc6 promoter in this cell line.
Differential Expression of Transcription Factors May Be Responsible for the Altered Transcription of Cdc6 —It is likely
that the sub-optimal interaction of the putative transcription
factors with the Cdc6 promoter resulted in the reduced Cdc6
transcription in PC3 cells. Promoter mapping showed a dramatic reduction in the transcription efficiency not only between
BPH-1 and PC3 cells but also between constructs C and B. The
difference between these two constructs was that, in construct
B three C/EBP sites (two in tandem), two NF1 sites in tandem,
one NFB, and one Oct1 transcription factor binding sites were

Cdc6 Expression in Prostate Cancer
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FIG. 5. Western blot analysis of the transcription factors in
nuclear extracts (50 g) of BPH and PC3 cells.

FIG. 4. Luciferase expression in transiently transfected BPH
and PC3 cells. A, Cdc6 promoter-luciferase constructs and putative
transcription factor binding sites. B, relative levels of luciferase transcription. Data represent mean ⫾ S.D. of five different experiments.

deleted. To rule out the possibility of reduced transcription of
Cdc6 in PC3 cells linked to reduced expression of specific transcription factors, the concentration of Oct1, NF1, NFB, and
C/EBP transcription factors in BPH-1 and PC3 cells was determined next by Western blot using specific antibodies and nuclear extracts from both cell lines (Fig. 5). Our result showed a
substantially reduced expression of Oct1 (Fig. 5A) in the nuclear extracts from PC3 cells compared with BPH-1 cells,
whereas NFB was up-regulated in PC3 cells (Fig. 5B). The

expression of NF1 did not differ between these two cell lines
(Fig. 5C). C/EBP expression was undetectable in both cell lines.
We have also monitored the concentration of the E2F transcription factor in BPH-1 and PC3 cells by Western blot, because
E2F plays an important role in Cdc6 transcription. Interestingly, a significant reduction in the expression of E2F in PC3
cells compared with BPH-1 cells was noted (Fig. 5D).
Mutation in the E2F Binding Sites Improved the Promoter
Activity in PC3 Cells but Not to the Level Obtained in BPH-1
Cells—It has been shown that E2F acts as a negative regulator
of Cdc6 transcription during G0/G1 through active repression
by pRb, E2F䡠DP complex by occupying two E2F sites adjacent
to the transcription start site (37, 38). To determine the role of
E2F on Cdc6 transcription in BPH-1 and PC3 cells, we have
monitored the expression of luciferase following transfection of
construct C containing two mutated E2F sites. A 43% increase
in the promoter activity was obtained in the mutant construct
C upon transfection into BPH-1 cells (p ⬍ 0.2) indicating the
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FIG. 3. Immunohistochemical analysis of CDC6 in prostate tissues. A and B, normal; C and D, PIN; E and F, tumor. A2, A3, B2, and B3,
immunohistochemical staining for CDC6 showing strong reactivity in non-neoplastic glands in comparison with weak staining in an adenocarcinoma (E2, E3, F2, and F3). C2, C3, D1, and D2, immunohistochemical staining for CDC6 in areas of PIN showing distinct reactivity.
(Magnification: A2, A3, C2, C3, E2, and E3, ⫻100; A1, B1, B2, B3, C1, D1, D2, E1, F1, F2, and F3, ⫻400).
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elimination of repression by a possible Rb䡠E2F complex as
proposed by other investigators (Fig. 6) (37, 38). The activity of
the mutant Cdc6 promoter construct transfected into PC3 cells
was also increased significantly (86%, p ⬍ 0.003) but not to the
same level as that obtained by the wild type or mutated construct C following transfection into BPH-1 cells. These results
suggest that other transcription regulatory proteins may be
involved in regulating Cdc6 expression in PC3 cells.
DISCUSSION

FIG. 6. Luciferase expression driven by the doubly mutated
Cdc6 promoter. Data represent mean ⫾ S.D. of four separate experiments (*, p ⬍ 0.02; **, p ⬍ 0.002).

TABLE II
Univariate analysis of Cdc6 expression
Variable

Outcomea

Observations

log10Cdc6

UI
AD or PIN

9
15

n

17
a

UI, uninvolved; AD, adenocarcinoma.

Odds ratio

3.1

N

Mean

⫾S.D.

7
10

6.1364123
5.0277647

0.6452855
1.0852465

p value

AUC

0.06

0.800
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In this study, the expression of CDC6, a key molecular component that regulates the onset of S phase, in prostate cancer
has been assessed. Using a variety of methods a 25–70% loss of
Cdc6 transcripts in prostate adenocarcinoma cells was detected. It was unlikely to detect a reduced transcription of Cdc6
in prostate cancer, because it is one of the evolutionarily conserved key proteins that maintain DNA replication in tight
control. Our study showed that the down-regulation of CDC6 in
prostate cancer was associated with phenotypic characteristics
of aggressive prostate cancer (Figs. 2 and 3).
Although prostate cell lines provide a homogeneous cell population that is convenient for data interpretation, especially for
gene expression profiling, they do not represent the true phenotype of prostate cancer. Analysis of the transcript profile of
Cdc6 in human prostate provided a similar pattern of Cdc6
expression in adenocarcinoma to the prostate cancer cell lines
(Fig. 2). To avoid the heterogeneity inherent in prostate tissue
samples of adenocarcinoma, which often exhibit normal uninvolved prostatic epithelium, PIN, and adenocarcinoma in close
proximity to one another, laser-captured microdissected areas
of histologically normal and carcinomatous tissues were used,
which provided nearly homogeneous cell populations. A consistent loss of Cdc6 transcripts in adenocarcinoma compared
with matched normal tissues authenticates its down-regulation. In addition, the extent of loss of expression correlates with
the phenotypic characteristics of the carcinoma showing an
inverse relationship with the Gleason score and invasiveness

(Table I). Organ-confined disease with a Gleason score of 6
showed a relatively higher level of Cdc6 expression compared
with the carcinoma with a Gleason score greater than or equal
to 7 and with extension to the margin of seminal vesicle or the
bladder. Univariate analysis of the Cdc6 expression profile in
24 human prostate samples containing eight matched pairs of
adenocarcinoma and adjacent normal tissue indicates the
strong potential of Cdc6 as a marker for advanced prostate
cancer (Table II). Our RT-PCR result also correlates with the
immunohistochemical detection of the protein product in histologic section of human prostate with a loss of staining in
adenocarcinoma and uniform staining of both nucleus and cytoplasm of histologically normal prostate glands. Staining of
CDC6 in some carcinoma cell nuclei may indicate partial expression and nuclear targeting of the expressed CDC6 or nonspecific staining by the antibody, although there is a substantial loss of overall staining (Fig. 3).
A number of studies (23, 39 – 41) on the precise role of CDC6
in the regulation of initiation of DNA replication have reported
a periodic transcription, subcellular localization, and degradation of CDC6 in proliferating cells that restricts DNA synthesis
to only once per cell cycle and that maintains proper timing of
mitosis. The potential uses of CDC6 and MCM proteins as
markers of proliferation of and for the detection of abnormal
cells in cervical smears and tumors in brain tissues have been
demonstrated also (32, 33). Contrary to these reports, our study
showed that a decreased expression of CDC6 is associated with
aggressive prostate cancer. Prostate cancer is a heterogeneous
and complex disease that may shift from an androgen-dependent growth phase to androgen independence, and this may
result in gene expression profiles that are dissimilar to other
cancers.
The mechanism by which CDC6 expression is differentially
regulated in BPH-1 and PC3 cells is unclear. Our Cdc6 reporter
assay indicated a 50- to 100-fold reduced promoter activity in
PC3 cells (Fig. 4B, construct C). Because no mutation could be
detected in the promoter sequence obtained from PC3 cells and
luciferase transcription driven by SV40 promoter (control plasmid) remained the same in both cell lines, it is possible that a
variation in the pool of specific transcription factors between
PC3 and BPH cell lines contributes to the reduced efficiency of
Cdc6 transcription. Although a truncated Cdc6 promoter without putative C/EBP, NFB, Oct1, and NF1 binding sites (construct B) exhibited an overall decrease in the luciferase activity
in both cell lines, it maintained a 16-fold higher promoter
activity in BPH-1 cells compared with PC3 cells. Interestingly,
deletion of 403 bases from the 5⬘-end of construct B (construct
A) in which no consensus transcription factor binding site was
detected completely abolished the promoter activity in both cell
lines. Despite the fact that the truncated promoter in construct
A contained three E2F, three Sp1, and one NF1 site it was
unable to transcribe luciferase at a detectable level, indicating
possible interaction of unknown transacting factors with the
element upstream of this region.
Fine mapping of the upstream sequence of the Cdc6 promoter showed that the addition of the NFB binding site (construct D) restored the transcription level similar to that of
construct C in both cell lines. However, inclusion of 11 addi-
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up-regulated in prostate cancer (43). p16 is inactivated in many
primary tumors and encodes a protein that inhibits cyclin-dependent kinases (44). This counterintuitive expression profile
also demonstrates the complexity of prostate carcinoma and
may represent a feedback mechanism to counteract increased
cell proliferation. Similarly, overexpression of mutant p53 is
associated with advanced prostate carcinoma (45) and is responsible for the loss of function of the wild type p53 by forming
heterodimers. In contrast, a consistent allelic loss at the Rb
locus and mutations in the Rb gene, a negative regulator of cell
cycle, have been identified in clinical samples of prostate cancer
and prostate cancer cell lines. Loss of function of Rb is associated with increased availability of active E2F, which eventually stimulates transcription of S phase proteins.
It is unusual that the lack of expression of CDC6 is associated with aggressive prostate cancer. A significant understanding of the role of CDC6 in regulating DNA replication has been
achieved in the past few years. CDC6 is the key regulator of
initiation of DNA synthesis, and a lack of functional CDC6 can
delay S phase entry. It is also proposed that CDC6 may be
responsible for the timing of mitosis, because human CDC6 is
present during S, G2, and M phases unlike its ortholog in
Schizosaccharomyces pombe (Cdc18), and degradation of CDC6
is required for exiting mitosis (38). In support of this assumption, inactivation of Cdc18 and CDC6 in S. cerevisiae and S.
pombe resulted in mitosis in the absence of DNA replication
(29, 30). It can be speculated that CDC6 may play an equally
important role in regulating the G2 and M phases, and this
function could be linked to aberrant cell proliferation in cancer
as a result of the loss of functional CDC6. Further research in
this area is needed to understand the role of CDC6 in prostate
cancer.
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tional bases upstream of the NFB binding site containing a
putative C/EBP binding site (construct E) inhibited luciferase
expression significantly in BPH-1 cells, suggesting a possible
nearby negative regulatory region. Addition of the NF1 and
Oct1 binding sites (constructs F and G) increased the transcription efficiency back to the same level as obtained with construct
C. It is noteworthy that none of the constructs containing
various lengths of the promoter were able to restore luciferase
expression in PC3 cells. It is possible that either a lack of
specific transcription factors or the inability of specific factors
to assemble to trans-activate Cdc6 transcription in PC3 cells is
responsible for the difference in transcriptional efficiency.
Our data also provide evidence that there is a disproportional expression of transcription factors, such as Oct1, NFB,
and E2F, between these two cell lines. Expression of NFB was
noticeably higher but Oct1 and E2F concentrations were significantly lower in PC3 cells compared with that in BPH-1 cells.
It can be speculated that the differential expression of these
transcription factors may influence Cdc6 transcription in these
prostate cell lines, although, other than E2F, it is not known
whether these transcription factors are true regulators of Cdc6
transcription. E2F is one of the key regulators of Cdc6 transcription, which acts as a positive and negative regulator of
Cdc6 depending on the cell cycle. In early phases of the cell
cycle, E2F sites are occupied by pRb, p107, and/or p130 bound
to E2F䡠DP complexes, but Cdc6 transcription does not occur
until cells enter mid-to-late G1 phase (42). Transcription activation by E2F probably requires displacement of the inhibitory
complex through interaction with other transcription factors. It
is interesting that none of the constructs were able to improve
luciferase expression in PC3 cells. It is possible that the interaction of E2F with the E2F binding sites is essential for orchestrating interaction of other transcription factors even though
the promoter containing only the E2F sites was unable to drive
luciferase transcription. Inefficient transcription by the Cdc6
promoter following point mutations in the two E2F binding
sites in serum-stimulated cells suggests a pivotal role of E2F in
Cdc6 transcription through positive regulation (37). At the
same time, point mutation in two E2F binding sites also eliminates the negative regulation of Cdc6 transcription by E2F
that is mediated through occupying the E2F binding sites as an
inhibitory complex (37). In support of this finding, our experiments using the Cdc6 promoter containing two mutated E2F
sites significantly improved Cdc6 promoter activity of both
transfected cell lines (Fig. 5). Nevertheless, luciferase expression in PC3 cells was far from being close to that in BPH-1 cells.
It is possible that the reduced expression of E2F in PC3 cells
may be responsible for the lack of interaction with the E2F
sites despite the intact binding sites. Inefficient interaction of
E2F may be the determining factor for the loss of Cdc6 transcription in PC3 cells. However, it is unclear whether this is the
primary reason for the loss of Cdc6 transcription, and further
research is needed to understand the roles of E2F and other
interactors on altered transcription of Cdc6 in prostate cancer.
Studies are underway to understand the molecular events of
Cdc6 regulation and whether these transcription factors are
directly involved in Cdc6 transcription in prostate cells. However, this report demonstrates a significant difference in the
efficiency of Cdc6 transcription and a corresponding alteration
in the concentration of transcription factors that may be involved in regulating Cdc6 transcription in PC3 cells.
Analysis of expression of other negative regulators of the cell
cycle, such as p16INK4a, p15INK4b, and p18INK4c in prostate
cancer, did not show any apparent correlation to tumor grade,
stage, and Gleason score, with the exception of p16 (43). Despite the fact that p16 is a negative regulator of cell cycle, it is
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